The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 4, 2009, Pages 1137-1144

  Mulligan, Kathleen ^a,b   Khatami, Hootan ^a,b   Schwarz, Jean Marc ^a,b,c   Sakkas, Giorgos K ^a,b   Depaoli, Alex M ^d   Tai, Viva W ^a,b   Wen, Michael J ^a,b   Lee, Grace A ^a,e   Grunfeld, Carl ^a,e   Schambelan, Morris ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c Touro University   (United States)

^d AMGEN INC   (United States)

^e SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RECOMBINANT LEPTIN; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CALORIC INTAKE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; ENERGY EXPENDITURE; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLYCOGENOLYSIS; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERINSULINEMIA; HYPOLIPEMIA; INJECTION SITE DISCOMFORT; INJECTION SITE REACTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID METABOLISM; LIPOATROPHY; LIPOLYSIS; MALE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TREATMENT OUTCOME;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 65249130126     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1588     Document Type: Article

References (47)

1. Reitman ML, Gavrilova O 2000 A-ZIP/F-1 mice lacking white fat: a model for understanding lipoatrophic diabetes. Int J Obes Relat Metab Disord 24(Suppl 4): S11-S14
2. Shimomura l, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, Goldstein JL, Brown MS 1998 Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 12:3182-3194
3. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M, Reitman ML 2000 Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 105:271-278
4. Nagy GS, Tsiodras S, Martin LD, Avihingsanon A, Gavrila A, Hsu WC, Karchmer AW, Mantzoros CS 2003 Human immunodeficiency virus type 1-related lipoat- rophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis 36:795-802
5. Wohl D, Scherzer R, Heymsfield S, Simberkoff M, Sidney S, Bacchetti P, Grunfeld C 2008 The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 48:44-52
6. Reitman ML, Arioglu E, Gavrilova O, Taylor SI 2000 Lipoatrophy revisited. Trends Endocrinol Metab 11:410-416
7. Haque WA, Shimomura I, Matsuzawa Y, Garg 2002 A Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 87:2395-2398
8. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL 1999 Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipo- dystrophy. Nature 401:73-76
9. Asilmaz E, Cohen P, Miyazaki M, Dobrzyn P, Ueki K, Fayzikhodjaeva G, Soukas AA, Kahn CR, Ntambi JM, Socci ND, Friedman JM 2004 Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J Clin Invest 113:414-424
10. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A 2002 Leptin-replace- ment therapy for lipodystrophy. N Engl J Med 346:570-578
11. Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS 2006 Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 91:2605-2611
12. Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N, Tanaka T, Chusho H, Miyazawa T, Hayashi T, Hosoda K, Ogawa Y, DePaoli AM, Fukushima M, Nakao K 2007 Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 92:532-541
13. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M 1998 "Buffalo hump" in men with HIV-1 infection. Lancet 351:867-870
14. Naressi A, Couturier C, Castang I, de Beer R, Graveron-Demilly D 2001 Java-based graphical user interface for MRUI, a software package for quantitation of in two/medical magnetic resonance spectroscopy signals. Comput Biol Med 31:269-286
15. Szczepaniak LS, Babcock EE, Schick F, Dobbins RL, Garg A, Burns DK, McGarry JD, Stein DT 1999 Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol 276:E977-E989
16. DeFronzo RA, Tobin JD, Andres R 1979 Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223
17. Matsuda M, DeFronzo RA 1997 In vivo measurement of insulin sensitivity in humans. In: Drasnin B, Rizza R, eds. Clinical research in diabetes and obesity. Vol 1. Methods, assessment, and metabolic regulation. Totowa, NJ: Humana Press, Inc.; 23-65
18. Wolfe RR 1992 Radioactive and stable isotope tracers in biomedicine: principles and practice of kinetic analysis. New York: Wiley-Liss
19. Hellerstein MK, Neese RA 1992 Mass isotopomer distribution analysis: a technique for measuring biosynthesis and turnover of polymers. Am J Physiol 263:E988-E1001
20. Neese RA, Schwarz JM, Faix D, Turner S, Letscher A, Vu D, Hellerstein MK 1995 Gluconeogenesis and intrahepatic triose phosphate flux in response to fasting or substrate loads. J Biol Chem 270:14452-14463
21. Ferrannini E 1988 The theoretical bases of indirect calorimetry: a review. Metabolism 3:287-301
22. Scherzer R, Shen W, Bacchetti P, Kotler D, Lewis CE, Shlipak MG, Punyanitya M, Heymsfield SB, Grunfeld C 2008 Comparison of dual-energy X-ray ab- sorptiometry and magnetic resonance imaging-measured adiposetissue depots in HIV-infected and control subjects. Am J Clin Nutr 88:1088-1096
23. Genuth S, Alberti KG, Bennett P, Buse J, DeFronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P 2003 Follow-upreport on the diagnosis of diabetes mellitus. Diabetes Care 26:3160-3167
24. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCamish M 1999 Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282:1568-1575
25. Kotler DP, Muurahainen N, Grunfeld C, Wanke C, Thompson M, Saag M, Bock D, Simons G, Gertner JM 2004 Effects of growth horm one on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 35:239-252
26. Grunfeld C, Thompson M, Brown SJ, Richmond G, Lee D, Muurahainen N, Kotler DP 2007 Recombinant human growth horm one totreat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr 45:286 -297
27. LoJ C, Mulligan K, Noor M, Schwarz J-M, Halvorsen RA, GrunfeldC, Schambelan M 2001 The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 86:3480-3487
28. Schwarz JM, Mulligan K, Lee J, Lo JC, Wen M, Noor MA, Grunfeld C, Schambelan M 2002 Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 87:942-945
29. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S 2007 Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 357: 2359-2370
30. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S 2004 Met- abolic effects of rosiglitazonein HIV lipodystrophy: arandomized, controlled trial. Ann Intern Med 140:786-794
31. van Wijk JP, de Koning EJ, Cabezas MC, op't Roodt J, Joven J, Rabelink TJ, Hoepelman AI 2005 Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 143:337-346
32. Mulligan K, Yang Y, Wininger DA, Koletar SL, Parker RA, Alston-Smith BL, Schouten JT, Fielding RA, Basar MT, Grinspoon S 2007 Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS 21:47-57
33. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S 2000 Met- formin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 284:472-477
34. Kohli R, Shevitz A, Gorbach S, Wanke C 2007 A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. HIV Med 8:420 -426
35. Smith SR, Zachwieja JJ 1999 Visceral adipose tissue: a critical review of intervention strategies. Int J Obes Relat Metab Disord 23:329-335
36. Barzilai N, Wang J, Massilon D, Vuguin P, Hawkins M, Rossetti L 1997 Leptin selectively decreases visceral adiposity and enhances insulin action. J Clin Invest 100:3105-3110
37. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB 2002 Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415:339-343
38. Lee Y, Yu X, Gonzales F, Mangelsdorf DJ, Wang MY, Richardson C, Witters LA, Unger RH 2002 PPARα is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci USA 99:11848-11853
39. Aberg JA, Zackin RA, Brobst SW, Evans SR, Alston BL, Henry WK, Glesby MJ, Torriani FJ, Yang Y, Owens SI, Fichtenbaum CJ 2005 A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 21:757-767
40. Mallon PW, Miller J, Kovacic JC, Kent-Hughes J, Norris R, Samaras K, Feneley MP, Cooper DA, Carr A 2006 Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men-a randomized, placebo-controlled study. AIDS 20:1003-1010
41. Calza L, Colangeli V, Manfredi R, Legnani G, Tampellini L, Pocaterra D, Chiodo F 2005 Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 19:1103-1105
42. Dube MP, Wu JW, Aberg JA, Deeg MA, Alston-Smith BL, McGovern ME, Lee D, Shriver SL, Martinez AI, Greenwald M, Stein JH 2006 Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther 11:1081-1089
43. Gerber JG, Kitch DW, Fichtenbaum CJ, Zackin RA, Charles S, Hogg E, Acosta EP, Connick E, Wohl D, Kojic EM, Benson CA, Aberg JA 2008 Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 47:459-466
44. Petersen KF, OralE A, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, De Paoli AM, Taylor SI, Gorden P, Shulman GI 2002 Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 109: 1345-1350
45. Ke Y, QiuJ, Ogus S, Shen WJ, Kraemer FB, Chehab FF 2003 Overexpression of leptin in transgenic mice leads to decreased basal lipolysis, PKA activity, and perilipin levels. Biochem Biophys Res Commun 312:1165-1170
46. Sekhar RV, Jahoor F, White AC, Pownall HJ, Visnegarwala F, Rodriguez- Barradas MC, Sharma M, Reeds PJ, Balasubramanyam A 2002 Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab 283: E332-E337
47. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE 2003 Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46:459 -469